Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

NCT06224049 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

T-cell Lymphoma

Interventions

BIOLOGICAL: hNeo-T
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

BGI, China

Collaborators

[object Object]